ArticleCancer medicine2026
A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum-Based Agents Using the FDA Adverse Event Reporting System Database.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveImmune checkpoint inhibitors (ICIs) combined with platinum-based compounds are commonly used in the treatment of certain malignant tumors. This study aims to analyze adverse events (AEs) associated with the combination therapy of ICIs and platinum-based compounds by using the FAERS database.
methodsThis study retrieved relevant adverse event (AE) data from the FAERS database (2008-2024) and conducted a retrospective analysis of the collected AEs. Multiple disproportionality analysis algorithms were employed, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).
resultsAnalysis of 28,585 reports identified 27 significant SOC-level signals, strongest for hematological (ROR = 6.3), endocrine (ROR = 14.3), and hepatobiliary disorders (ROR = 4.49). Key PTs included malignant neoplasm progression (ROR = 16), febrile neutropenia (ROR = 15.31), and myocarditis (ROR = 16.3). 45.5% of AEs occurred within 1 month (median onset: 38 days). Combination therapy showed lower rates vs. monotherapy for malignancy progression and nephrotoxicity, but higher neurotoxicity (628 neuropathy cases).
conclusionThe combination exhibits distinct early-onset toxicities (early-onset hematological/endocrine/hepatic) and novel risks (neuropathy/myocarditis/leukemia), necessitating enhanced initial monitoring and subgroup-specific management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.